Citigroup Inc. Purchases 150,517 Shares of Smith & Nephew SNATS, Inc. $SNN

Citigroup Inc. boosted its holdings in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) by 44.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 486,661 shares of the medical equipment provider’s stock after acquiring an additional 150,517 shares during the period. Citigroup Inc. owned approximately 0.11% of Smith & Nephew SNATS worth $17,661,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of SNN. Bank of Montreal Can raised its position in shares of Smith & Nephew SNATS by 321.6% during the second quarter. Bank of Montreal Can now owns 3,429,829 shares of the medical equipment provider’s stock worth $105,056,000 after purchasing an additional 2,616,301 shares during the period. JPMorgan Chase & Co. raised its holdings in Smith & Nephew SNATS by 6,663.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,210,655 shares of the medical equipment provider’s stock worth $37,082,000 after buying an additional 1,192,755 shares during the period. ABC Arbitrage SA lifted its stake in Smith & Nephew SNATS by 1,063.4% in the second quarter. ABC Arbitrage SA now owns 898,635 shares of the medical equipment provider’s stock valued at $27,525,000 after buying an additional 821,393 shares in the last quarter. Todd Asset Management LLC bought a new position in Smith & Nephew SNATS in the third quarter valued at approximately $26,319,000. Finally, Goldman Sachs Group Inc. boosted its holdings in shares of Smith & Nephew SNATS by 49.2% in the first quarter. Goldman Sachs Group Inc. now owns 1,771,401 shares of the medical equipment provider’s stock valued at $50,255,000 after buying an additional 583,809 shares during the period. 25.64% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms recently commented on SNN. Kepler Capital Markets raised shares of Smith & Nephew SNATS to a “strong-buy” rating in a research report on Monday, November 17th. Wall Street Zen lowered Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 21st. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research report on Wednesday, January 21st. Canaccord Genuity Group decreased their price objective on Smith & Nephew SNATS from $36.00 to $34.00 and set a “hold” rating for the company in a report on Tuesday, November 11th. Finally, Royal Bank Of Canada cut Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a research note on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $35.75.

Smith & Nephew SNATS Trading Up 0.7%

NYSE:SNN opened at $36.94 on Friday. Smith & Nephew SNATS, Inc. has a 52-week low of $23.91 and a 52-week high of $38.79. The company has a quick ratio of 1.40, a current ratio of 3.00 and a debt-to-equity ratio of 0.60. The stock’s 50-day simple moving average is $34.16 and its 200 day simple moving average is $34.97.

Smith & Nephew SNATS Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.